aTyr Pharma Shares Surge on FDA Agreement for Pivotal Efzofitimod Trial

Shares of aTyr Pharma (NASDAQ: ATYR) surged 9.1% in pre-market trading after the company announced it has reached an agreement with the U.S. Food and Drug Administration (FDA) on the protocol for a pivotal Phase 3 trial. The study will evaluate efzofitimod, aTyr's lead therapeutic candidate, for the treatment of chronic, symptomatic pulmonary sarcoidosis.

FDA Greenlights Trial Design

According to a company announcement, the alignment with the FDA clears a significant regulatory hurdle for the development of efzofitimod. aTyr Pharma stated it now expects to begin study-related activities in the fourth quarter of 2026.

The company also plans to use the trial results to pursue regulatory submissions for the drug in both the United States and Europe. The news provides investors with a clearer timeline for the drug's path to potential commercialization.

Study Details and Supporting Data

The planned Phase 3 trial is designed as a global, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of efzofitimod. The primary endpoint will be forced vital capacity (FVC), a key measure of lung function.

Ad

The trial's design is supported by a subgroup analysis from a previous Phase 3 study, known as EFZO-FIT™. Data from that analysis, presented at the WASOG 2026 Congress, showed that patients with restrictive lung disease receiving a 5.0 mg/kg dose of efzofitimod experienced clinically meaningful improvements in FVC and other patient-reported outcomes compared to placebo.

Market Reaction and Outlook

The stock's significant pre-market gain was notable as it came on a day when broader U.S. equity markets were under pressure. The FDA protocol agreement removes a critical source of uncertainty for investors, reinforcing the company's strategy in interstitial lung disease, a therapeutic area with significant unmet medical need.

The positive development follows a challenging period for the company, which included a corporate restructuring and workforce reduction earlier in the year. The clear path forward for its lead asset appears to have renewed investor confidence.